Abstract
Methylphenidate is a leading first-line treatment for ADHD (AD/HD). This stimulant has long been suspected to adversely affect sleeping patterns of treated individuals, especially children. There are few studies on the effects of recently developed longer-acting methylphenidate treatments, such as once-daily oral or transdermal formulations, on sleep. The authors examined eight indices of sleep behavior among children treated with either of these two methylphenidate preparations or placebo in a randomized, double-blind, multicenter, parallel-group study. The main predictor of sleep problems was baseline numbers or severity of preexisting sleep problems, whereas the different treatments and placebo varied little in their propensity to elicit such problems. There was no significant relationship between dosage and severity or frequency of sleep problems. The authors found little evidence that methylphenidate treatment (at least in sustained-release forms) was a significant cause of sleep problems in treated children who were carefully titrated to an optimal dose.
References
Jan 1, 1983·Sleep·L GreenhillM Davies
Jul 1, 1997·Journal of the American Academy of Child and Adolescent Psychiatry·J KaufmanN Ryan
Oct 23, 1997·Journal of the American Academy of Child and Adolescent Psychiatry·M Dulcan
Nov 14, 1998·Journal of Learning Disabilities·A RingA Weizman
Oct 16, 1999·Journal of Child and Adolescent Psychopharmacology·M A Stein
Feb 24, 2001·Journal of the American Academy of Child and Adolescent Psychiatry·L L GreenhillT Wigal
Nov 9, 2001·Journal of the American Academy of Child and Adolescent Psychiatry·L L GreenhillK Kroeger
Jan 8, 2004·Journal of Clinical Psychopharmacology·Stephen V FaraoneJoseph Biederman
Jun 9, 2005·Expert Review of Neurotherapeutics·Philip K CappCharles Conlon
Jan 27, 2007·Sleep·R Bart SangalDouglas Kelsey
Mar 4, 2008·The Journal of Clinical Psychiatry·Robert L FindlingRaymond D Pratt
Citations
Jun 22, 2012·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Mark A SteinLaura Hlavaty
Feb 18, 2014·CNS Drugs·Robert L Findling, Steven Dinh
Jan 19, 2012·Behavioral Sleep Medicine·Gretchen Stuckert NobleBrad Brubaker
Nov 23, 2013·Journal of Child and Adolescent Psychopharmacology·Jessica R BarrettGiovanni Giaroli
Jun 11, 2011·BMC Medicine·Kevin M AntshelStephen V Faraone
May 3, 2014·CNS Drugs·David R CoghillRichard Civil
May 16, 2009·Expert Opinion on Drug Metabolism & Toxicology·Oscar G Bukstein
Aug 5, 2009·Behavioral and Brain Functions : BBF·Lenard A AdlerThomas Roth
Mar 12, 2013·Behavioral Sleep Medicine·Vincent MoreauCharles M Morin
Oct 19, 2016·Journal of Child and Adolescent Psychopharmacology·Judith OwensAkwete Adjei
Apr 11, 2017·Expert Opinion on Drug Safety·Ann Childress
Sep 22, 2012·Journal of Attention Disorders·Rachel E FargasonKaren L Gamble
Apr 23, 2010·Journal of Attention Disorders·Barrie K MarchantDouglas G Kondo
Jun 25, 2010·Journal of Attention Disorders·John M Giblin, Aaron L Strobel
Nov 26, 2015·The Cochrane Database of Systematic Reviews·Ole Jakob StorebøChristian Gluud
Jan 7, 2010·Journal of Sleep Research·Barbara C GallandBarry J Taylor
Jan 23, 2010·International Clinical Psychopharmacology·Hyo-Won KimHee Jeong Yoo
Nov 26, 2011·Expert Review of Clinical Pharmacology·Josephine EliaKarin Borgmann-Winter
Dec 20, 2012·Psychiatry Investigation·Sang Heon LeeJong Hun Lee
Mar 25, 2016·Journal of Developmental and Behavioral Pediatrics : JDBP·Stephen P BeckerJeffery N Epstein
Sep 15, 2015·Journal of Clinical Psychopharmacology·Marco PozziSonia Radice
Jul 2, 2017·CNS Drugs·David R CoghillAlessandro Zuddas
Jan 7, 2021·Journal of Attention Disorders·Upasana BondopadhyayAndrew N Coogan
Apr 13, 2021·CNS Spectrums·Christoph U CorrellMichael Huss